Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adam Levitt

Vascular Surgery Orlando, FL Medical Doctor

NPI 1881673077 CMS profile 84902

80 W Michigan St, Orlando, FL 32806

Open in the dashboard

General payments

$14,414

178 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$25,001

1 holding reported · through program year 2025

Through program year 2025, Adam Levitt of Orlando, FL is reported in the CMS Open Payments database as having received $14,414 across 178 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $25,001 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,692 16
2024 General $6,658 33
2023 General $2,800 32
2022 General $1,061 28
2021 General $555 16
2020 General $653 22
2019 General $995 31
2025 Ownership $25,001 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Levitt
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Adam Levitt were reported at $1,692. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Adam Levitt Vascular Surgery median Middle half National median
2019 $995 $796 $226–$2,363 $163
2020 $653 $348 $118–$1,110 $114
2021 $555 $471 $158–$1,421 $132
2022 $1,061 $725 $222–$2,183 $149
2023 $2,800 $836 $257–$2,440 $160
2024 $6,658 $909 $252–$2,619 $164
2025 $1,692 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. NovApproach Spine, LLC $4,250 2 payments
  2. W. L. Gore & Associates, Inc. $3,707 56 payments
  3. AngioDynamics, Inc. $1,941 3 payments
  4. Boston Scientific Corporation $861 15 payments
  5. Bard Peripheral Vascular, Inc. $747 15 payments
  6. Silk Road Medical, Inc. $453 7 payments
  7. Endologix, Inc. $280 3 payments
  8. Cardiovascular Systems Inc. $250 9 payments
  9. Abbott Laboratories $228 4 payments
  10. Philips Electronics North America Corporation $200 3 payments
  11. Other $1,498 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,748 169 payments
  2. Consulting Fee $4,250 2 payments
  3. Long term medical supply or device loan $1,920 2 payments
  4. Travel and Lodging $1,496 5 payments
Products named General payments · program years 2019–2025
  1. OneLIF $4,250 2 payments
  2. GORE TAG Thoracic Endoprosthesis $1,651 11 payments
  3. VenaCure 1470 Pro Et $960 1 payment
  4. VenaCure 1470 Pro Id $960 1 payment
  5. GORE TAG Thoracic Branch Endoprosthesis $653 8 payments
  6. ENROUTE Transcarotid Stent $453 7 payments
  7. ENROUTE Transcarotid Neuroprotection System $453 7 payments
  8. WATCHMAN Access System $254 5 payments
  9. TAG Thoracic Endoprosthesis $236 3 payments
  10. GORE VIABAHN VBX Balloon Expandable Endo $231 3 payments
  11. Other $5,731 181 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

272

Median for Vascular Surgery: 122

Drug cost

$20,475

Median for Vascular Surgery: $14,135

Branded share of claims

62.9%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 19 $9,818
Eliquis Apixaban Brand 14 $7,947
Clopidogrel Clopidogrel Bisulfate Brand 138 $1,370
Cilostazol Generic 42 $1,215
Oxycodone Hcl Generic 59 $124

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 95 billing codes

Paid by Medicare

$207,908

Of which drugs: $266

Medicare patients

330

Average age 75

Services billed

2,513

169 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 58%
Arthritis 58%
Chronic kidney disease 48%
Diabetes 39%
Heart failure 31%
Atrial fibrillation 31%
Depression 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 11 545 $159
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 15 1,012 $106

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record